Evidence map›Paper›PMID 34641933›Full record

ArticleOrphanet journal of rare diseases2021

The impact of demographic and clinical characteristics on the trajectories of health-related quality of life among patients with Fabry disease.

Solrun Sigurdardottir, Birgitte Bjerkely, Trond G Jenssen, Per Mathisen, Charlotte von der Lippe, Kristin Ørstavik, Ketil Heimdal, Dag Olav Dahle, Mina Susanne Weedon-Fekjær, Olga Solberg and 1 more

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Solrun SigurdardottirCentre for Rare Disorders, Oslo University Hospital, Postboks 4950 Nydalen, 0424, Oslo, Norway. sosigu@ous-hf.no.ORCID 0000-0002-7194-3570
Birgitte BjerkelyCentre for Rare Disorders, Oslo University Hospital, Postboks 4950 Nydalen, 0424, Oslo, Norway.
Trond G JenssenDepartment of Surgery, Inflammation Medicine and Transplantation, Section of Nephrology, Oslo University Hospital, Rikshospitalet HF, Oslo, Norway.
Per MathisenDepartment of Cardiology, Oslo University Hospital, Rikshospitalet HF, Oslo, Norway.
Charlotte von der LippeCentre for Rare Disorders, Oslo University Hospital, Postboks 4950 Nydalen, 0424, Oslo, Norway.
Kristin ØrstavikDepartment of Neurology, Section for Rare Neuromuscular Disorders, Oslo University Hospital, Rikshospitalet HF, Oslo, Norway.
Ketil HeimdalDepartment of Medical Genetics, Oslo University Hospital, Rikshospitalet HF, Oslo, Norway.
Dag Olav DahleDepartment of Surgery, Inflammation Medicine and Transplantation, Section of Nephrology, Oslo University Hospital, Rikshospitalet HF, Oslo, Norway.
Mina Susanne Weedon-FekjærCentre for Rare Disorders, Oslo University Hospital, Postboks 4950 Nydalen, 0424, Oslo, Norway.
Olga SolbergCentre for Rare Disorders, Oslo University Hospital, Postboks 4950 Nydalen, 0424, Oslo, Norway.
Hege K PihlstrømDepartment of Surgery, Inflammation Medicine and Transplantation, Section of Nephrology, Oslo University Hospital, Rikshospitalet HF, Oslo, Norway.
Oslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFabry disease (FD) is an X-linked lysosomal storage disorder characterized by multiorgan dysfunction. Since individuals with FD usually experience progressive clinical disease manifestations, their health-related quality of life (HRQOL) is expected to change over time. However, there is limited longitudinal research examining HRQOL outcomes in individuals with FD. We aimed to: assess longitudinal outcomes in HRQOL in adults with FD; examine the physical- and mental HRQOL trajectories at the initial registration (baseline), 3-5 year, and 7-13 year follow-ups; and evaluate the possible associations of age, sex and medical complications with the physical- and mental HRQOL trajectories.

methodsForty-three individuals with FD (53% female) who were aged 18 to 81 years at baseline attended clinical follow-up visits between 2006 and 2020. Medical records were extracted retrospectively. Demographics and the 36-item Short-Form Health Survey (SF-36) were recorded at scheduled visits, except for the last data collection which was prospectively obtained in 2020. The physical (PCS) and mental (MCS) composite scores (SF-36) were chosen as outcome measures.

resultsThe eight SF-36 domain scores were stable over a span of 13 years, and only physical- and social functioning domains worsened clinically over this follow-up period. Mean baseline SF-36 domain scores were all significantly lower (decreased HRQOL) in the FD sample compared with Norwegian population norms. Two hierarchical linear models were run to examine whether demographics and medical complications (measured at the last clinical visit) predicted physical and mental HRQOL trajectories. Age above 47 years (p < 0.001), male sex (p = 0.027), small fibre neuropathy (p < 0.001), renal dysfunction (p < 0.001), and cerebrovascular events (p = 0.003) were associated with lower HRQOL over time. No significant interactions were found between the time of follow up and the abovementioned predictors of HRQOL.

conclusionsOverall HRQOL trajectories remained stable between baseline, 3-5 year, and 7-13 year follow-ups, with the majority of individuals reporting decreased physical and mental HRQOL. Medical complications in combination with older age and male sex are important predictors of lower HRQOL in FD. Awareness of this relationship is valuable both for health care providers and for patients. The findings provide indicators that can guide treatment decisions to improve physical and mental HRQOL outcomes.

Indexed as

Fabry DiseaseQuality of LifeAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesSurveys and QuestionnairesERTFabry diseaseHRQOLKidney diseaseLongitudinal studiesNeuropathic painQuality of lifeSF-36

Identifiers

PMID34641933
PMCPMC8506470
OpenAlexW3206019871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.